1. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. (January 2020) Authors: Lind, M.; Gettinger, S.; Borghaei, H.; Brahmer, J.; Chow, L.; Burgio, M.; De Castro Carpeno, J.; Pluzanski, A.; Arrieta, O.; Frontera, O. Aren; Chiari, R.; Butts, C.; Wojcik-Tomaszewska, J.; Coudert, B.; Garassino, M.; Ready, N.; Felip, E.; Garcia, M. Alonso; Waterhouse, D.; Domine, M. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Variability in gut microbiota response to an inulin-type fructan prebiotic within an in vitro three-stage continuous colonic model system. (July 2017) Authors: Healey, G.; Murphy, R.; Butts, C.; Brough, L.; Rosendale, D.; Blatchford, P.; Stoklosinski, H.; Coad, J. Journal: Bioactive carbohydrates and dietary fibre Issue: Volume 11(2017) Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Waiting Time Intervals for Non-small Cell Lung Cancer Diagnosis and Treatment in Alberta: Quantification of Intervals and Identification of Risk Factors Associated with Delays. Issue 12 (December 2016) Authors: Kim, J.O.A.; Davis, F.; Butts, C.; Winget, M. Journal: Clinical oncology Issue: Volume 28:Issue 12(2016) Page Start: 750 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗